Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study
- Citation:
- Blood vol 130 (Suppl 1) 467
- Meeting Instance:
- ASH 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3235
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180820, U10CA180888, and U24CA196171
- Corr. Author:
- Authors:
- Konstanze Döhner Christian Thiede Richard A. Larson Thomas W. Prior Guido Marcucci Jürgen Krauter Michael Heuser Francesco Lo-Coco Josep F. Nomdedeu Sumithra Mandrekar Ben L. Sanford Kristine Laumann Susan Geyer Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel Sanz Joseph M. Brandwein Theo de Witte Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Yuan Cheng Celine Pallaud Richard M. Stone Hartmut Döhner Clara D. Bloomfield
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007, LAPS-WI013
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: